Rabies is a zoonotic disease that still causes 59,000 human deaths each year,and rabies vaccine is the most effective way to control the disease.Our previous studies suggested that the maturation of DC plays an import...Rabies is a zoonotic disease that still causes 59,000 human deaths each year,and rabies vaccine is the most effective way to control the disease.Our previous studies suggested that the maturation of DC plays an important role in enhancing the immunogenicity of rabies vaccine.Flt3L has been reported to own the ability to accelerate the DC maturation,therefore,in this study,a recombinant rabies virus expressing mouse Flt3L,designated as LBNSE-Flt3L,was constructed,and its immunogenicity was characterized.It was found that LBNSE-FU3L could enhance the maturation of DC both in vitro and in vivo,and significantly more TFH cells and Germinal Center B(GC B)cells were generated in mice immunized with LBNSE-FU3L than those immunized with the parent virus LBNSE.Consequently,expressing of Flt3L could elevate the level of virus-neutralizing antibodies(VNA)in immunized mice which provides a better protection from a lethal rabies virus challenge.Taken together,our study extends the potential of Flt3L as a good adjuvant to develop novel rabies vaccine by enhancing the VNA production through activating the DC—Tfh^GC B axis in immunized mice.展开更多
目的:探讨自体DC-CIK细胞联合化疗治疗局部晚期不可切除或转移性胃腺癌的临床疗效和安全性。方法:收集2014年11月至2016年7月就诊于中国医学科学院肿瘤医院的32例晚期胃腺癌患者,按照随机对照表法以1∶1分为DC-CIK细胞联合用药组与单药...目的:探讨自体DC-CIK细胞联合化疗治疗局部晚期不可切除或转移性胃腺癌的临床疗效和安全性。方法:收集2014年11月至2016年7月就诊于中国医学科学院肿瘤医院的32例晚期胃腺癌患者,按照随机对照表法以1∶1分为DC-CIK细胞联合用药组与单药组(每组各16例),两组患者基线资料均衡一致。分别采集PBMC,经实验室体外诱导培养获得DC和CIK细胞。单药组采用替吉奥/奥沙利铂或顺铂化疗方案,联合用药组采用相同化疗方案+DC-CIK细胞治疗。分析比较两组患者治疗前后外周血T淋巴细胞亚群、临床治疗效果、不良反应发生情况和生活质量改善情况。结果:联合用药组患者治疗前后外周血T细胞亚群无明显变化(P>0.05),单药组患者化疗后外周血中CD3^+、CD3^+CD4^+、CD3^+CD8^+、CD3^-CD56^+细胞百分比明显低于治疗前(均P<0.05)。联合用药组患者疾病控制率、无进展生存期均高于单药组(87.5%vs 50.0%,8.9 vs 4.4个月;均P<0.05),两组中位生存期分别为18.0和14.0个月(P>0.05)。联合用药组治疗后明显改善了患者因化疗毒副反应或病情本身引起的体力匮乏和失眠,未见治疗相关严重不良反应。结论:DC-CIK细胞联合化疗可明显改善局部晚期不可切除转移性胃腺癌患者免疫状态和生活质量,提高了临床疗效,无明显不良反应。展开更多
基金supported by the National Program on Key Research Project of China (2016YFD0500400 and 2017YFD0501701)the National Natural Science Foundation of China (31872494, 31402176, 31372419, and 31522057)+2 种基金the Fundamental Research Funds for the Central Universities (No. 2662016QD036 to MZ)the Ministry of Science and Technology of China (863 program, No. 2011AA10A212)the Ministry of Agriculture of China (Special Fund for Agro-scientific Research in the Public Interest, No. 201303042 to ZFF)
文摘Rabies is a zoonotic disease that still causes 59,000 human deaths each year,and rabies vaccine is the most effective way to control the disease.Our previous studies suggested that the maturation of DC plays an important role in enhancing the immunogenicity of rabies vaccine.Flt3L has been reported to own the ability to accelerate the DC maturation,therefore,in this study,a recombinant rabies virus expressing mouse Flt3L,designated as LBNSE-Flt3L,was constructed,and its immunogenicity was characterized.It was found that LBNSE-FU3L could enhance the maturation of DC both in vitro and in vivo,and significantly more TFH cells and Germinal Center B(GC B)cells were generated in mice immunized with LBNSE-FU3L than those immunized with the parent virus LBNSE.Consequently,expressing of Flt3L could elevate the level of virus-neutralizing antibodies(VNA)in immunized mice which provides a better protection from a lethal rabies virus challenge.Taken together,our study extends the potential of Flt3L as a good adjuvant to develop novel rabies vaccine by enhancing the VNA production through activating the DC—Tfh^GC B axis in immunized mice.
文摘目的:探讨自体DC-CIK细胞联合化疗治疗局部晚期不可切除或转移性胃腺癌的临床疗效和安全性。方法:收集2014年11月至2016年7月就诊于中国医学科学院肿瘤医院的32例晚期胃腺癌患者,按照随机对照表法以1∶1分为DC-CIK细胞联合用药组与单药组(每组各16例),两组患者基线资料均衡一致。分别采集PBMC,经实验室体外诱导培养获得DC和CIK细胞。单药组采用替吉奥/奥沙利铂或顺铂化疗方案,联合用药组采用相同化疗方案+DC-CIK细胞治疗。分析比较两组患者治疗前后外周血T淋巴细胞亚群、临床治疗效果、不良反应发生情况和生活质量改善情况。结果:联合用药组患者治疗前后外周血T细胞亚群无明显变化(P>0.05),单药组患者化疗后外周血中CD3^+、CD3^+CD4^+、CD3^+CD8^+、CD3^-CD56^+细胞百分比明显低于治疗前(均P<0.05)。联合用药组患者疾病控制率、无进展生存期均高于单药组(87.5%vs 50.0%,8.9 vs 4.4个月;均P<0.05),两组中位生存期分别为18.0和14.0个月(P>0.05)。联合用药组治疗后明显改善了患者因化疗毒副反应或病情本身引起的体力匮乏和失眠,未见治疗相关严重不良反应。结论:DC-CIK细胞联合化疗可明显改善局部晚期不可切除转移性胃腺癌患者免疫状态和生活质量,提高了临床疗效,无明显不良反应。
